-
Product Insights
NewLikelihood of Approval Analysis for Substance (Drug) Abuse
Overview How likely is it that the drugs in Substance (Drug) Abuse will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Substance (Drug) Abuse Overview Substance abuse refers to the problematic pattern...
-
Product Insights
NewLikelihood of Approval Analysis for Diabetic Complications
Overview How likely is it that the drugs in Diabetic Complications will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diabetic Complications Overview Diabetes is a chronic autoimmune disease if untreated or...
-
Product Insights
NewLikelihood of Approval Analysis for Dementia
Overview How likely is it that the drugs in Dementia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dementia Overview Dementia is the decline in cognitive abilities that impacts a person's...
-
Product Insights
NewLikelihood of Approval Analysis for Generalized Anxiety Disorder (GAD)
Overview How likely is it that the drugs in Generalized Anxiety Disorder (GAD) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Generalized Anxiety Disorder (GAD) Overview Generalized anxiety disorder is a...
-
Product Insights
NewLikelihood of Approval Analysis for Meningitis
Overview How likely is it that the drugs in Meningitis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Meningitis Overview Meningitis is the inflammation of the meninges, protective membranes covering the...
-
Product Insights
NewLikelihood of Approval Analysis for Multiple Sclerosis
Overview How likely is it that the drugs in Multiple Sclerosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Multiple Sclerosis Overview Multiple sclerosis (MS) is an autoimmune disease in which...
-
Thematic Analysis
NewPsychedelics Therapeutics Development and Trends, 2024
This report provides a summary of the current and future state of the psychedelic therapeutic sector, offering a high-level analysis of key trends and developments within the industry, including regulatory, clinical, and market dynamics. The report identifies the broader changes within the evolving psychedelic industry, facilitating informed decision-making for relevant sectors.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lumateperone Tosylate in Schizoaffective Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lumateperone Tosylate in Schizoaffective Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lumateperone Tosylate in Schizoaffective Disorder Drug Details: Lumateperone tosylate (Caplyta) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lumateperone Tosylate in Insomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lumateperone Tosylate in Insomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lumateperone Tosylate in Insomnia Drug Details: Lumateperone tosylate (Caplyta) is a butyrophenone...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lumateperone Tosylate in Bipolar II Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lumateperone Tosylate in Bipolar II Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lumateperone Tosylate in Bipolar II Disorder Drug Details: Lumateperone tosylate...